Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMarstons Regulatory News (MARS)

Share Price Information for Marstons (MARS)

Share Price is delayed by 15 minutes
Get Live Data
50.90    0.70 (1.39%)
Bid:
50.80
Ask:
51.10
Spread: 0.30 (0.591%)
Market Cap: £322.13m
MARS Live PriceLast checked at - London Stock Exchange

Intraday Marstons Share Chart

FORM 8 (OPD)

11 Feb 2021 07:00

RNS Number : 6864O
Marston's PLC
11 February 2021
Β 

FORM 8 (OPD)

Β 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

Β 

1. KEY INFORMATION

Β 

(a) Full name of discloser:

MARSTON'S PLC

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

N/A

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

MARSTON'S PLC

(d) Is the discloser the offeror or the offeree?

OFFEREE

(e) Date position held:

The latest practicable date prior to the disclosure

8 February 2021

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

Β 

Β 

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

Β 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

Β 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

Β 

Class of relevant security:

Β 

Β 

Β 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

Nil

Nil

(2) Cash-settled derivatives:

Β 

Nil

Nil

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

Nil

Nil

Β 

TOTAL:

Nil

Nil

Β 

All interests and all short positions should be disclosed.

Β 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental FormΒ 8 (Open Positions).

Β 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

Β 

(b) Rights to subscribe for new securities

Β 

Class of relevant security in relation to which subscription right exists:

N/A

Details, including nature of the rights concerned and relevant percentages:

N/A

Β 

Β 

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

Β 

Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure:

Β 

(a) Interests held by the directors of Marston's Plc and their close relatives and related trusts:

Β 

Name

Number of ordinary shares

Percentage of total issued share capital (excluding share options) (%)

Andrew Andrea

332,773

0.050%

Ralph Findlay

1,290,475

0.195%

Carolyn Bradley

25,000

0.004%

Bridget Lea

50,000

0.008%

Octavia Morley

29,634

0.004%

Matthew Roberts

25,000

0.004%

William Rucker

200,000

0.030%

Β 

(b) Interests held as options or awards under the share plans of Marston's PLC by the directors of Marston's PLC and their close relatives and related trusts who are not exempt principal traders for the purposes of Rule 8 of the Code:

Name

Share Plan

Number of ordinary shares (under option)

Vesting date

Exercise price (per share) (Β£)

Andrew Andrea

2018 LTIP

473,033

2021

Nil

2019 LTIP

372,124

2022

Nil

Ralph Findlay

2018 SAYE

20,224

2021

0.89

2018 LTIP

706,287

2021

Nil

2019 LTIP

555,620

2022

Nil

Β 

Β 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

Β 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

Β 

4. OTHER INFORMATION

Β 

(a) Indemnity and other dealing arrangements

Β 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

Β 

NONE

Β 

Β 

(b) Agreements, arrangements or understandings relating to options or derivatives

Β 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

Β 

NONE

Β 

Β 

(c) Attachments

Β 

Are any Supplemental Forms attached?

Β 

Supplemental Form 8 (Open Positions)

NO

Supplemental Form 8 (SBL)

NO

Β 

Β 

Date of disclosure:

10 February 2021

Contact name:

Anne-Marie Brennan, Group Secretary

Telephone number:

+44 (0) 1902 329516

Β 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

Β 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

Β 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
FEEDBLFFFLLEBBL
Date   Source Headline
26th Jun 20232:23 pmRNSDirector/PDMR Shareholding
26th Jun 20231:08 pmRNSDirector/PDMR Shareholding
25th May 20238:16 amRNSDirector/PDMR Shareholding
24th May 20238:48 amRNSDirector/PDMR Shareholding
16th May 20237:00 amRNSRESULTS FOR THE 26 WEEKS ENDED 1 APRIL 2023
31st Mar 20237:00 amRNSAmendment and extension of debt facilities
22nd Mar 202310:19 amRNSHolding(s) in Company
24th Jan 20232:01 pmRNSResult of AGM
24th Jan 20237:00 amRNSTrading for the 16-week period to 21 January 2023
10th Jan 20233:07 pmRNSBlock listing Interim Review
6th Jan 20233:11 pmRNSHolding(s) in Company
3rd Jan 20239:42 amRNSHolding(s) in Company
21st Dec 20225:05 pmRNSConfirmation of Covenant Amendments
21st Dec 20222:34 pmRNSAnnual Financial Report
14th Dec 20229:00 amRNSDirector/PDMR Shareholding
6th Dec 20227:00 amRNSPreliminary Results for 52 weeks ended 1 Oct 2022
5th Dec 202212:31 pmRNSConfirmation of Final Results announcement date
30th Nov 202210:46 amRNSHolding(s) in Company
28th Nov 202212:55 pmRNSChange to Final Results date and update on trading
28th Nov 20229:59 amRNSHolding(s) in Company
25th Nov 202212:04 pmRNSHolding(s) in Company
17th Nov 20229:14 amRNSHolding(s) in Company
17th Nov 20227:09 amRNSDirector Declaration re: New Directorship
10th Nov 202210:47 amRNSHolding(s) in Company
9th Nov 20228:15 amRNSHolding(s) in Company
3rd Nov 20224:25 pmRNSHolding(s) in Company
3rd Nov 20223:05 pmRNSHolding(s) in Company
11th Oct 20227:00 amRNSTrading update for the 52 weeks to 1 October 2022
6th Oct 20229:31 amRNSCorrection re Holding(s) in Company
5th Oct 202212:15 pmRNSHolding(s) in Company
12th Sep 20229:43 amRNSDirector/PDMR Shareholding
5th Sep 202212:27 pmRNSDirector/PDMR Shareholding
2nd Sep 202210:14 amRNSDirector/PDMR Shareholding
31st Aug 20222:51 pmRNSHolding(s) in Company
27th Jul 20227:00 amRNSTrading update for the 42 weeks to 23 July 2022
11th Jul 202212:03 pmRNSBlock listing Interim Review
7th Jul 20229:55 amRNSHolding(s) in Company
29th Jun 20228:45 amRNSDirector/PDMR Shareholding
13th Jun 20228:30 amRNSDirector/PDMR Shareholding
30th May 20222:14 pmRNSHolding(s) in Company
25th May 20228:54 amRNSHolding(s) in Company
20th May 202210:15 amRNSDirector/PDMR Shareholding
19th May 20227:00 amRNSInvestor Meet Company Presentation
18th May 20227:00 amRNSRESULTS FOR THE 26 WEEKS ENDED 2 APRIL 2022
5th Apr 202212:39 pmRNSHolding(s) in Company
30th Mar 20228:28 amRNSDirector/PDMR Shareholding
28th Mar 20229:49 amRNSHolding(s) in Company
17th Mar 202210:18 amRNSHolding(s) in Company
8th Mar 202210:06 amRNSHolding(s) in Company
7th Mar 20227:00 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.